US · ALBT
Avalon GloboCare Corp.
- Sector
- Real Estate · Real Estate - Services
- Headquarters
- Freehold, NJ 07728
- Website
- avalon-globocare.com
Price · as of 2024-12-31
$0.42
Market cap 5.71M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $329.28 | +78,318.67% |
| Intrinsic Value(DCF) | $3.55 | +745.44% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $576.00 | $304.67 | $0.00 | $0.00 | $0.00 |
| 2019 | $219.00 | $103.31 | $0.00 | $0.00 | $0.00 |
| 2020 | $184.50 | $96.55 | $0.00 | $0.00 | $3.51 |
| 2021 | $102.00 | $98.11 | $0.00 | $0.00 | $0.00 |
| 2022 | $33.30 | $31.04 | $0.00 | $0.00 | $6.24 |
| 2023 | $5.78 | $25.89 | $0.00 | $0.00 | $0.00 |
| 2024 | $7.23 | $329.28 | $1.12 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Avalon GloboCare Corp.'s (ALBT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $329.28
- Current price
- $0.42
- AI upside
- +78,318.67%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.55
+745.44% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALBT | Avalon GloboCare Corp. | $0.42 | 5.71M | +78,319% | +745% | — | — | -0.86 | 0.95 | 5.08 | -2.28 | -0.20 | 0.95 | 20.09% | -369.56% | -592.72% | -109.23% | -35.45% | -38.03% | 1.10 | -2.02 | 0.23 | 0.21 | -0.96 | 43082.00% | 619.00% | -2387.00% | -73.38% | -0.36 | -35.74% | 0.00% | 0.00% | 49.71% | -2.39 | -2.37 | 8.82 | -6.88 |
| LRHC | La Rosa Holdings Corp. | $1.06 | 567.1K | +9,772% | +6,228% | — | — | -18218.44 | 101786.68 | 3764.42 | -21292.28 | -126127.65 | -23168.69 | 8.57% | -16.12% | -20.80% | -338.51% | -183.11% | -85.07% | 1.88 | -10.64 | 0.53 | 0.28 | -0.28 | 1444.00% | 11867.00% | 5848.00% | 0.00% | -0.35 | -49.10% | 0.00% | 0.00% | 0.00% | -23348.63 | -87078.05 | 3764.47 | 12319.70 |
| UK | Ucommune International Lt… | $0.52 | 1.04M | +7,560% | -15% | — | +136,938% | -0.08 | 0.06 | 0.04 | -0.78 | -0.01 | 0.06 | 0.08% | -29.86% | -45.79% | -92.61% | -41.12% | -16.70% | 1.04 | -39.53 | 0.99 | 0.77 | -0.55 | 100300.00% | -6202.00% | -13077.00% | -16.62% | 0.03 | -0.84% | 0.00% | 0.00% | 1231.48% | -0.40 | -19.77 | 0.12 | -20.33 |
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
- CEO
- Meng Li
- Employees
- 4
- Beta
- -0.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.55 ÷ $0.42) − 1 = +745.44% (DCF, example).